GLAXF
Price
$18.16
Change
-$0.00 (-0.00%)
Updated
Aug 7 closing price
Capitalization
103.73B
GSK
Price
$37.86
Change
+$0.28 (+0.75%)
Updated
Aug 8, 10:37 AM (EDT)
Capitalization
88.13B
82 days until earnings call
Interact to see
Advertisement

GLAXF vs GSK

Header iconGLAXF vs GSK Comparison
Open Charts GLAXF vs GSKBanner chart's image
GSK
Price$18.16
Change-$0.00 (-0.00%)
Volume$277
Capitalization103.73B
GSK
Price$37.86
Change+$0.28 (+0.75%)
Volume$2.4K
Capitalization88.13B
GLAXF vs GSK Comparison Chart in %
Loading...
GLAXF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GSK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GLAXF vs. GSK commentary
Aug 08, 2025

To understand the difference between Glaxosmithkline plc (GLAXF) vs. Glaxosmithkline plc - ADR (GSK) it is enough to know the definitions of ADR

ADR - American depositary receipt (ADR) is a certificate issued by a U.S. depositary bank representing a specified number of shares (often 1 share) of a foreign company's stock. ADRs are denominated in U.S. dollars and trade on U.S. stock markets and OTC depending on the ADRs classification.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 08, 2025
Stock price -- (GLAXF: $18.16 vs. GSK: $37.58)
Brand notoriety: GLAXF and GSK are both not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: GLAXF: 6% vs. GSK: 69%
Market capitalization -- GLAXF: $103.73B vs. GSK: $88.13B
GLAXF [@Pharmaceuticals: Major] is valued at $103.73B. GSK’s [@Pharmaceuticals: Major] market capitalization is $88.13B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GLAXF’s FA Score shows that 1 FA rating(s) are green whileGSK’s FA Score has 2 green FA rating(s).

  • GLAXF’s FA Score: 1 green, 4 red.
  • GSK’s FA Score: 2 green, 3 red.
According to our system of comparison, both GLAXF and GSK are a good buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GLAXF’s TA Score shows that 3 TA indicator(s) are bullish while GSK’s TA Score has 5 bullish TA indicator(s).

  • GLAXF’s TA Score: 3 bullish, 6 bearish.
  • GSK’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, GSK is a better buy in the short-term than GLAXF.

Price Growth

GLAXF (@Pharmaceuticals: Major) experienced а -4.52% price change this week, while GSK (@Pharmaceuticals: Major) price change was +1.16% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.43%. For the same industry, the average monthly price growth was +6.77%, and the average quarterly price growth was +13.43%.

Reported Earning Dates

GSK is expected to report earnings on Oct 29, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (-0.43% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GLAXF($104B) has a higher market cap than GSK($88.1B). GLAXF has higher P/E ratio than GSK: GLAXF (17.36) vs GSK (14.01). GSK YTD gains are higher at: 13.633 vs. GLAXF (7.935). GLAXF has higher annual earnings (EBITDA): 10B vs. GSK (9.08B). GLAXF has more cash in the bank: 14B vs. GSK (4.99B). GSK has less debt than GLAXF: GSK (18B) vs GLAXF (33.3B). GLAXF has higher revenues than GSK: GLAXF (36.5B) vs GSK (30.3B).
GLAXFGSKGLAXF / GSK
Capitalization104B88.1B118%
EBITDA10B9.08B110%
Gain YTD7.93513.63358%
P/E Ratio17.3614.01124%
Revenue36.5B30.3B120%
Total Cash14B4.99B280%
Total Debt33.3B18B185%
FUNDAMENTALS RATINGS
GLAXF vs GSK: Fundamental Ratings
GLAXF
GSK
OUTLOOK RATING
1..100
1073
VALUATION
overvalued / fair valued / undervalued
1..100
8
Undervalued
9
Undervalued
PROFIT vs RISK RATING
1..100
10071
SMR RATING
1..100
4040
PRICE GROWTH RATING
1..100
6058
P/E GROWTH RATING
1..100
3429
SEASONALITY SCORE
1..100
6565

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GLAXF's Valuation (8) in the null industry is in the same range as GSK (9) in the Pharmaceuticals Major industry. This means that GLAXF’s stock grew similarly to GSK’s over the last 12 months.

GSK's Profit vs Risk Rating (71) in the Pharmaceuticals Major industry is in the same range as GLAXF (100) in the null industry. This means that GSK’s stock grew similarly to GLAXF’s over the last 12 months.

GSK's SMR Rating (40) in the Pharmaceuticals Major industry is in the same range as GLAXF (40) in the null industry. This means that GSK’s stock grew similarly to GLAXF’s over the last 12 months.

GSK's Price Growth Rating (58) in the Pharmaceuticals Major industry is in the same range as GLAXF (60) in the null industry. This means that GSK’s stock grew similarly to GLAXF’s over the last 12 months.

GSK's P/E Growth Rating (29) in the Pharmaceuticals Major industry is in the same range as GLAXF (34) in the null industry. This means that GSK’s stock grew similarly to GLAXF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GLAXFGSK
RSI
ODDS (%)
Bullish Trend 1 day ago
62%
Bullish Trend 1 day ago
78%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
60%
Bullish Trend 1 day ago
53%
Momentum
ODDS (%)
Bearish Trend 1 day ago
49%
Bearish Trend 1 day ago
48%
MACD
ODDS (%)
Bearish Trend 1 day ago
54%
Bullish Trend 1 day ago
71%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
56%
Bullish Trend 1 day ago
59%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
57%
Bearish Trend 1 day ago
51%
Advances
ODDS (%)
Bullish Trend 12 days ago
64%
Bullish Trend 5 days ago
58%
Declines
ODDS (%)
Bearish Trend 3 days ago
51%
Bearish Trend 3 days ago
54%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
67%
Bullish Trend 1 day ago
69%
Aroon
ODDS (%)
Bearish Trend 1 day ago
45%
Bearish Trend 1 day ago
39%
View a ticker or compare two or three
Interact to see
Advertisement
GLAXF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GSK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
AVDE75.470.54
+0.72%
Avantis International Equity ETF
TBG32.660.05
+0.15%
TBG Dividend Focus ETF
PYN5.15N/A
N/A
PIMCO New York Municipal Income Fund III
NDMO9.80-0.05
-0.51%
Nuveen Dynamic Municipal Opportunities Fund
LST36.70-0.32
-0.86%
Leuthold Select Industries ETF

GLAXF and

Correlation & Price change

A.I.dvisor indicates that over the last year, GLAXF has been loosely correlated with GSK. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if GLAXF jumps, then GSK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GLAXF
1D Price
Change %
GLAXF100%
N/A
GSK - GLAXF
37%
Loosely correlated
+2.26%
OPHLY - GLAXF
9%
Poorly correlated
-0.45%
HAWPF - GLAXF
8%
Poorly correlated
N/A
ORINY - GLAXF
6%
Poorly correlated
-12.25%
GIKLY - GLAXF
5%
Poorly correlated
N/A
More

GSK and

Correlation & Price change

A.I.dvisor indicates that over the last year, GSK has been closely correlated with NVS. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if GSK jumps, then NVS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GSK
1D Price
Change %
GSK100%
+2.26%
NVS - GSK
67%
Closely correlated
+2.13%
AZN - GSK
64%
Loosely correlated
+0.12%
PFE - GSK
56%
Loosely correlated
+1.25%
SNY - GSK
53%
Loosely correlated
+2.71%
AMGN - GSK
51%
Loosely correlated
+0.01%
More